Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07738107 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ATR 1072 in Participants With PRKAG2 Syndrome

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 2026 to Sep 14, 2026
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.
Trial Details
NCT Number NCT07738107
Lead Sponsor Atrium Therapeutics
Conditions
(from sponsor)		 Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome
Related terms Cardiomyopathies, Glycogen Storage Disease, Hypertrophy, Wolff-Parkinson-White Syndrome
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov